ASTRAZENECA PLC |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 12,246 GBX | -0.58% |
|
+1.06% | +15.53% |
| 08:38pm | FDA extends review of Ascendis Pharma's hormone disorder therapy | RE |
| 02:05pm | ASTRAZENECA : Buy rating from JP Morgan | ZD |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
Financials (USD)
| Sales 2024 * | 51.48B | Sales 2025 * | 55.17B | Capitalization | 238B |
|---|---|---|---|---|---|
| Net income 2024 * | 8.62B | Net income 2025 * | 10.29B | EV / Sales 2024 * | 5.03 x |
| Net Debt 2024 * | 20.66B | Net Debt 2025 * | 13.65B | EV / Sales 2025 * | 4.57 x |
| P/E ratio 2024 * |
28.2
x | P/E ratio 2025 * |
23.5
x | Employees | 89,900 |
| Yield 2024 * |
1.99% | Yield 2025 * |
2.1% | Free-Float | 96.5% |
More Fundamentals
* Assessed data
More news
Latest transcript on AstraZeneca PLC
More press releases
More news
| 1 day | -0.52% | ||
| 1 week | +1.06% | ||
| Current month | +1.53% | ||
| 1 month | +11.08% | ||
| 3 months | +25.94% | ||
| 6 months | +20.22% | ||
| Current year | +15.53% |
1 week
12 004.00
12 442.00
1 month
10 764.0012 488.00
Current year
9 461.0012 488.00
1 year
9 461.0012 488.00
3 years
7 842.8212 488.00
5 years
5 739.0012 488.00
10 years
3 680.0012 488.00
| Managers | Title | Age | Since |
|---|---|---|---|
Pascal Soriot
CEO | Chief Executive Officer | 64 | 12-09-30 |
Aradhana Sarin
DFI | Director of Finance/CFO | 50 | 21-07-31 |
Cindy Hoots
CTO | Chief Tech/Sci/R&D Officer | 56 | 19-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Sherilyn McCoy
BRD | Director/Board Member | 65 | 17-09-30 |
Ahmed Hamdy
PRN | Corporate Officer/Principal | 59 | 13-01-31 |
Philip Broadley
BRD | Director/Board Member | 63 | 17-04-26 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 9.20% | 11 M€ | +0.83% | - | |
| 5.39% | 200 M€ | +17.77% | ||
| 5.17% | 17 M€ | +6.46% | - | |
| 4.89% | 693 M€ | +13.18% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-14 | 12,246 | -0.58% | 1 150 481 |
| 24-05-13 | 12,318 | -0.42% | 4,031,899 |
| 24-05-10 | 12,370 | +0.31% | 1,408,188 |
| 24-05-09 | 12,332 | +0.55% | 1,329,958 |
| 24-05-08 | 12,264 | +1.20% | 2,091,841 |
Delayed Quote London S.E., May 14, 2024 at 11:35 am EDT
More quotes
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
BUY
Number of Analysts
22
Last Close Price
154.6
USD
Average target price
166.8
USD
Spread / Average Target
+7.85%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +15.53% | 240B | |
| +30.86% | 682B | |
| +30.35% | 586B | |
| -3.53% | 364B | |
| +18.15% | 327B | |
| +3.93% | 285B | |
| +10.16% | 209B | |
| -8.14% | 203B | |
| +8.13% | 165B | |
| -1.55% | 161B |
- Stock Market
- Equities
- AZN Stock